Showing 2461-2470 of 4166 results for "".
- Bausch + Lomb Initiates First Clinical Trial for Technolas Teneo Excimer Laser in the United Stateshttps://modernod.com/news/bausch-lomb-initiates-first-clinical-trial-for-technolas-teneo-excimer-laser-in-the-united-states/2479560/Bausch + Lomb announced that it has initiated the first in a series of U.S. clinical trials to evaluate the safety and efficacy of the Technolas Teneo excimer laser for vision correction surgery for myopia and myopic astigmatism. “This is an exciting milestone for our organization, as it’s
- Bausch + Lomb to Initiate Series of US Clinical Trials for Technolas Teneo Excimer Laserhttps://modernod.com/news/bausch-lomb-to-initiate-series-of-us-clinical-trials-for-technolas-teneo-excimer-laser/2476482/Bausch + Lomb announced it will initiate a series of US clinical trials to evaluate the safety and efficacy of Technolas Teneo excimer laser for vision correction surgery for myopia and myopic astigmatism. The company expects the clinical trials to begin by July 2019. “The global LASIK mar
- Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in GAhttps://modernod.com/news/annexon-presents-new-neuroprotection-data-showing-anx007-protects-vision-and-vision-associated-structures-in-ga/2482268/Annexon presented new analyses of ANX007 from the phase 2 ARCHER trial in geographic atrophy (GA), and new preclinical data on the role of C1q in the pathogenic elimination of photoreceptor synapses and their protection with C1q blockade in GA. ANX007 is a first-in-class, non-pegylated
- The National Center for Children’s Vision and Eye Health at Prevent Blindness Convenes New Children’s Vision Equity Alliancehttps://modernod.com/news/the-national-center-for-childrens-vision-and-eye-health-at-prevent-blindness-convenes-new-childrens-vision-equity-alliance/2480464/
- Global Vision Campaign Aims to Achieve 1 Million Vision Screenings and Eye Exams for World Sight Dayhttps://modernod.com/news/global-vision-campaign-aims-to-achieve-1-million-vision-screenings-and-eye-exams-for-world-sight-day/2480305/
- AIVITA Biomedical’s Stem Cell Therapeutic in Vision Loss Published in Investigative Ophthalmology & Vision Sciencehttps://modernod.com/news/aivita-biomedicals-stem-cell-therapeutic-in-vision-loss-published-in-investigative-ophthalmology-vision-science/2478398/AIVITA Biomedical announced the publication of the peer-reviewed manuscript, “Retina organoid transplants develop photoreceptors and improve visual function in RCS rats with RPE dysfunction,” in the journal Investigative Ophthalmology & Visual Science. The
- Pixium Vision Announces Receipt of € 1.8 Million from the French Government as Research Tax Credithttps://modernod.com/news/pixium-vision-announces-receipt-of-eur-18-million-from-the-french-government-as-research-tax-credit/2481661/Pixium Vision SA announced that it has received a €1.8 million Research Tax Credit from the French government. This cash injection will help extend the company’s cash runway until the end of September 2023, providing more flexibility to pursue its longer-term f
- Johnson & Johnson Vision to Launch Acuvue Oasys Max 1-Day Contact Lenses in Several Marketshttps://modernod.com/news/johnson-johnson-vision-to-launch-acuvue-oasys-max-1-day-contact-lenses-in-several-markets/2480914/Johnson & Johnson Vision announced it has received FDA clearance, Health Canada approval, and completed CE Mark activities for its latest contact lens, Acuvue Oasys Max 1-Day and Acuvue Oasys Max 1-Day Multifocal. The announcement comes during the 125th Annual AOA Congress and 54th<
- Belkin Vision's Automated, Non-Contact Glaucoma Laser Treatment Receives CE Markhttps://modernod.com/news/belkin-visions-eagle-receives-ce-mark-under-mdr/2480859/Israel-based Belkin Vision announced that it has received CE Mark for its Eagle device, making it the first automated, non-contact glaucoma laser treatment available within Europe. The CE Mark was granted under Medical Device Regulation (MDR) from its notified body DEKRA.
- EyeMed Vision Care Names Matt MacDonald Presidenthttps://modernod.com/news/eyemed-vision-care-names-matt-macdonald-president/2481204/EyeMed has appointed Matt MacDonald to the role of President. Mr. MacDonald succeeds Lukas Ruecker who has decided to step down after 9 years for personal reasons. Mr. MacDonald has been with EyeMed since 2013, and most recently served as Chief Operations Officer. Prior to that, he